A single-shot vaccine for COVID-19

Cheryl Sanders
August 1, 2020

J&J's vaccine uses a common cold virus known as adenovirus type 26 or Ad26 to ferry coronavirus proteins into cells in the body, causing the body to mount an immune defense against the virus.

The British government, in the meantime, has signed a deal with pharmaceutical giants GlaxoSmithKline (GSK) and Sanofi Pasteur for 60 million doses of a potential Covid-19 vaccine if the tests prove to be successful.

This means that after the registration one more clinical study of the vaccine will be conducted on 1,600 people.

The Philippines plans to buy 40 million doses worth $400 million for 20 million people, around a fifth of the country's 107 million population, the country's Finance Secretary Carlos Dominguez said.

Out of seven prototypes tested in the study, it found that Ad26-S.PP had the highest levels of neutralising antibodies to fight infection.

Six weeks later, all of the animals were exposed to the SARS-CoV-2 virus.

The head of the Russian Direct Investment Fund, Kirill Dmitriev, has likened what he said was Russia's success in developing a vaccine to the Soviet Union's 1957 launch of Sputnik 1, the world's first satellite. "Still, a two-shot vaccine will likely be more immunogenic, and thus both regimens are being evaluated in clinical trials".

Following the study, a Phase 1/2a first-in-human clinical trial of the vaccine candidate has now commenced in healthy volunteers in the U.S. and Belgium.

Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson said: "We are excited to see these pre-clinical data because they show our SARS-CoV-2 vaccine candidate generated a strong antibody response and provided protection with a single dose".

He said doctors and teachers would be the first to be vaccinated.

Depending on those results, J&J plans to start large-scale, phase 3 testing with a single-shot regimen in the second half of September.

Other reports by iNewsToday